Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-06-19 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation of loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015, regarding details of lost share certificates and stop transfer requests. It is addressed to the stock exchange and contains specific shareholder and share certificate details. This type of filing is a regulatory announcement related to share certificates and shareholder information, not a financial report or management information. It fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure without financial data or report content.
2023-06-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of the Establishment Inspection Report (EIR) from the US FDA for Lupin's API manufacturing facility. It is a disclosure pursuant to SEBI regulations and does not contain detailed financial data, management discussion, or full report content. The document is short (4086 characters) and serves as an announcement of a regulatory inspection outcome rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure.
2023-06-19 English
Lupin Receives EIR from U.S. FDA for its API Manufacturing Facility in Vizag.
Regulatory Filings Classification · 95% confidence The document is a press release dated June 19, 2023, announcing that Lupin Limited has received the Establishment Inspection Report (EIR) from the US FDA for its API manufacturing facility in Vizag, India. The text is a disclosure pursuant to SEBI regulations and is addressed to stock exchanges. It does not contain detailed financial data, management discussion, or full report content but is an announcement of receipt of a regulatory inspection report. The document length is 4230 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure, not as the full audit or annual report or any other detailed report type.
2023-06-19 English
Lupin Launches Thiamine Hydrochloride Injection USP in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product following FDA approval. It is addressed to stock exchanges and references a disclosure pursuant to a listing regulation. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is 4104 characters, which is relatively short and typical for a press release. There is no financial data, no detailed report, no voting results, no management changes, or other regulatory filings. Therefore, the document fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product by Lupin Limited following FDA approval of an ANDA by its alliance partner. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document is short (4089 characters), contains no financial statements or detailed financial analysis, and primarily serves as a corporate announcement of a business event. It does not contain quarterly or annual financial results, audit information, or management discussion. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report.
2023-06-19 English
Lupin Launches Darunavir Tablets in the United States
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Darunavir Tablets by Lupin Limited. It is addressed to stock exchanges and references a disclosure pursuant to SEBI regulations. The content focuses on product launch information and company background, without any financial statements, detailed financial performance, or regulatory filings. The document length is 3787 characters, which is relatively short and typical for a press release. There is no indication that this is an annual report, earnings release, or any other detailed financial or regulatory report. It is not a report publication announcement since it does not mention any report being attached or published. The document fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations that does not fit other specific categories.
2023-06-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.